Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is "blind" treatment dangerous?

Eur Respir J. 2011 May;37(5):1283-5. doi: 10.1183/09031936.00144710.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / therapeutic use*
  • Burkina Faso
  • Chronic Disease
  • HIV Infections / diagnosis
  • HIV Infections / immunology
  • Humans
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / isolation & purification
  • Sputum / microbiology*
  • Treatment Failure
  • Tuberculosis, Multidrug-Resistant / diagnosis
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / microbiology
  • Tuberculosis, Pulmonary / diagnosis
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / microbiology

Substances

  • Antitubercular Agents